Director Adam L. Roth filed a Form 4 with the SEC on November 9, 2026, disclosing the grant of 25,848 restricted stock units in Byrna Technologies Inc. on November 7, 2026, as part of his base compensation for the 2026-2027 Annual Meeting cycle.
Director Matthew R. McBrady filed a Form 4 with the SEC on November 9, 2026, disclosing the grant of 25,848 restricted stock units in Byrna Technologies Inc. as part of his base compensation for the 2026-2027 Annual Meeting cycle.
Byrna Technologies Inc. Chairman of the Board TJ Kennedy filed a Form 4 on November 9, 2026, disclosing the settlement of previously vested restricted stock units and the grant of new restricted stock units on November 7, 2026.
Randy Lee Stone, a director of CTS Corp, filed a statement of changes in beneficial ownership on November 9, 2026, reporting the acquisition of 2,813 restricted stock units on November 5, 2026, at a price of $0.
Director Donna Costello filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026.
Director Amy M. Dodrill filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026.
Director William S. Johnson filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026.
Director Robert Profusek filed a Form 4 with the SEC on November 9, 2026, reporting the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026, at no cost.
Director Alfonso G. Zulueta filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of 2,813 restricted stock units of CTS Corp on November 5, 2026, at no cost.
SOPHiA GENETICS SA Chief Executive Officer and Director Ross Muken filed a Form 4 on November 9, 2026, disclosing an open-market purchase of 20,000 ordinary shares on November 6, 2026.